Ultrasound contrast developer ImaRx Pharmaceutical is rampingup its manufacturing capacity and personnel lineup as it preparesfor the commercial launches of several new products.The Tucson, AZ, company last month tapped Henry "Pete"Manspeaker
Ultrasound contrast developer ImaRx Pharmaceutical is rampingup its manufacturing capacity and personnel lineup as it preparesfor the commercial launches of several new products.
The Tucson, AZ, company last month tapped Henry "Pete"Manspeaker as vice president and director of clinical operationsof its newly formed clinical research department. Manspeaker wasmost recently director of clinical research at Alliance Pharmaceuticalof San Diego.
Manspeaker will work in conjunction with ImaRx Pharmaceutical'sU.S. licensee, Du Pont Merck Pharmaceutical, on the completionof clinical trials related to ImaRx's Aerosomes (MRX-115) microbubble-basedultrasound contrast agent technology (SCAN 12/13/95). Aerosomesis about to begin phase III clinical trials.
Other agents ImaRx is developing include gastrointestinal MRIagent LumenHance; gastrointestinal ultrasound agent SonoRx; TomoRx,a CT agent for the gastrointestinal tract; and MRX-408, a thrombus-specificultrasound contrast agent.
The company also announced that a physical plant expansion, whichwill result in the construction of a new 18,000-square-foot facility,should be finished by late 1997. Following the completion of theproject, the company anticipates that it will double its workforce to 50 employees.
In other personnel moves, ImaRx announced that Thomas Fritz hasbeen promoted from director of operations to vice president andchief operating officer.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Emerging MRI Scoring System May Help Predict Recurrent and Metastatic Hepatocellular Carcinoma
February 12th 2025Preoperative use of the scoring system for gadoxetic acid-enhanced MRI demonstrated an average AUC of 85 percent and average specificity of 89 percent in external validation cohorts for pathologic features of hepatocellular carcinoma.